Skip to search formSkip to main contentSkip to account menu

tosedostat

Known as: 2-(2-(hydroxy(hydroxycarbamoyl)methyl)-4-methylpentanoylamino)-2-phenylethanoic acid cyclopentyl ester, Aminopeptidase inhibitor CHR-2797, Cyclopentyl (2S)-2-{(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4- methylpentanamido}-2-phenylacetate 
A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Aminopeptidase inhibitor CHR… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Tosedostat, an oral aminopeptidase inhibitor, has synergy with cytarabine and hypomethylating agents. We performed a Phase II… 
2015
2015
New anti‐malarial treatments are desperately required to face the spread of drug resistant parasites. Inhibition of… 
Review
2014
Review
2014
Introduction: Despite recent improvements in the scientific understanding of leukemia biology, the overall prognosis for adults… 
Highly Cited
2013
Highly Cited
2013
ABSTRACT Candida species are the cause of 60% of all mycoses in immunosuppressed individuals, leading to ∼150,000 deaths annually… 
Review
2013
Review
2013
Aminopeptidases represent a class of (zinc) metalloenzymes that catalyze the cleavage of amino acids nearby the N-terminus of… 
2013
2013
Microfluidic systems show great promise for single-cell analysis; however, as these technologies mature, their utility must be… 
Highly Cited
2010
Highly Cited
2010
PURPOSE To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797… 
2010
2010
Background:This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT… 
2009
2009
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary therapeutic activity…